| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/20/2003 | WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 02/20/2003 | WO2002068548A9 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 02/20/2003 | WO2002068387A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/20/2003 | WO2002067998A3 Devices and methods for the treatment of cancer |
| 02/20/2003 | WO2002066062A3 Enhancement of glp-2 activity |
| 02/20/2003 | WO2002064026A3 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 02/20/2003 | WO2002053170A3 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 02/20/2003 | WO2002026950A3 Transferases |
| 02/20/2003 | WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 02/20/2003 | WO2001091741B1 Compositions containing hexitol and an antiproliferative agent |
| 02/20/2003 | WO2001064949A9 Diagnostics and therapeutics for glaucoma |
| 02/20/2003 | WO2001056547B1 Preparation of aqueous clear solution dosage forms with bile acids |
| 02/20/2003 | US20030036633 DNA encoding bradykinin B1 receptor |
| 02/20/2003 | US20030036568 Permeation enhancers |
| 02/20/2003 | US20030036560 Methods and compositions for treating and preventing mucositis |
| 02/20/2003 | US20030036558 Useful in the treatment of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor. |
| 02/20/2003 | US20030036556 Zonisamide use in headache |
| 02/20/2003 | US20030036549 Methods for treating irritable bowel syndrome |
| 02/20/2003 | US20030036548 Method for treating anhedonia using dopamine agonists |
| 02/20/2003 | US20030036546 Administering an opioidergic composition, such as opiate antagonist, an opiate agonist and a combination thereof. |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036535 Physiological method of improving vision |
| 02/20/2003 | US20030036534 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 02/20/2003 | US20030036526 Activating a signaling cascade comprising, introducing leptin and/or a cytokine to a receptor complex comprising gp 130, to genes in neuro- endocrine cells or cells of neuro-endocrine origin. |
| 02/20/2003 | US20030036525 Hyaluronic acid and/or a salt thereof associated with/bound with an effective amount of anti-sense to the gene implicated in the disease or condition |
| 02/20/2003 | US20030036515 Method of treating hematologic tumors and cancers |
| 02/20/2003 | US20030036513 Reducing the effective dose of an anti-cancer agent by administering a redox clamping agent, especially Mesna, in conjunction with an anti-cancer agent. |
| 02/20/2003 | US20030036502 Methods for enhancing wound healing |
| 02/20/2003 | US20030036501 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 02/20/2003 | US20030036500 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 02/20/2003 | US20030036208 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system |
| 02/20/2003 | US20030036199 Kit for use in the diagnosis and treatment of cancer |
| 02/20/2003 | US20030036184 Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| 02/20/2003 | US20030036078 P5CRs as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | US20030036076 CADs as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | US20030036075 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders |
| 02/20/2003 | US20030035847 Acid mixture; anticancer, antitumor agents |
| 02/20/2003 | US20030035837 Mixture of drug with retarder; sustained release |
| 02/20/2003 | US20030035831 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/20/2003 | US20030035830 Method of administering liposomal encapsulated taxane |
| 02/20/2003 | US20030035827 Pharmaceutical compositions containing substrates of enabling enzymes to preferentially deliver drugs away from PBVC or GIC systems |
| 02/20/2003 | US20030035819 Skin care composition that mediates cell to cell communication |
| 02/20/2003 | US20030035816 Soluble ctla4 mutant molecules and uses thereof |
| 02/20/2003 | US20030035812 Administering vaccine |
| 02/20/2003 | US20030035801 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/20/2003 | US20030035795 Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor |
| 02/20/2003 | CA2810339A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | CA2607992A1 Bicyclic compound, production and use thereof |
| 02/20/2003 | CA2467919A1 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 02/20/2003 | CA2462200A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | CA2459071A1 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma |
| 02/20/2003 | CA2457624A1 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | CA2457400A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 02/20/2003 | CA2456942A1 Compositions and methods for modulation of darpp-32 phosphorylation |
| 02/20/2003 | CA2456939A1 Carbonic anhydrase inhibitors |
| 02/20/2003 | CA2456928A1 Cellular virus receptors and methods of use |
| 02/20/2003 | CA2456762A1 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | CA2456723A1 Inhibitors of her3 activity |
| 02/20/2003 | CA2456607A1 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | CA2456549A1 The treatment of lipodystrophy |
| 02/20/2003 | CA2456369A1 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | CA2456322A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | CA2456271A1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
| 02/20/2003 | CA2456247A1 Use of il-18 inhibitors in hypersensitivity disorders |
| 02/20/2003 | CA2456236A1 Methods of screening based on the egf receptor crystal structure |
| 02/20/2003 | CA2456223A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 02/20/2003 | CA2456175A1 Benzoquinone ansamycins |
| 02/20/2003 | CA2456034A1 Sustained-release medicines |
| 02/20/2003 | CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | CA2455585A1 Compounds for treating anhedonia |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2454648A1 Irinotecan for treatment of cancer |
| 02/20/2003 | CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454251A1 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | CA2454173A1 Stabilized oral suspension formulation |
| 02/20/2003 | CA2453913A1 Method for identifying substances which positively influence inflammatory conditions |
| 02/20/2003 | CA2453506A1 Pramipexole as an anticonvulsant |
| 02/20/2003 | CA2453485A1 Pramipexole for the treatment of adhd |
| 02/20/2003 | CA2453433A1 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | CA2451914A1 Combination therapy for the treatment of neurological disorders |
| 02/20/2003 | CA2451691A1 Use of r-nsaid compounds for anti-hiv treatment |
| 02/20/2003 | CA2450777A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | CA2428822A1 Modulators of p-selectin glycoprotein ligand 1 |
| 02/19/2003 | EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof |
| 02/19/2003 | EP1284298A2 Identification and use of molecules implicated in pain |
| 02/19/2003 | EP1284297A2 Identification and use of molecules implicated in pain |
| 02/19/2003 | EP1284151A1 Topical treatment of pain and to promote healing including capsaicin as an analgesic |
| 02/19/2003 | EP1284141A2 Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases |
| 02/19/2003 | EP1284137A1 Nonoral preparation having three-layer structure |
| 02/19/2003 | EP1283903A1 Drug screening systems and assays |
| 02/19/2003 | EP1283894A1 Use of baculovirus vectors in gene therapy |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283884A2 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 02/19/2003 | EP1283874A2 Novel deoxynucleoside kinase enzyme variants |
| 02/19/2003 | EP1283848A2 Protein complexes and assays for screening anti-cancer agents |